IL-13 in Moderate to Severe Atopic Dermatitis

CE / CME

Advanced IL-13 Targeting in Moderate to Severe Atopic Dermatitis 

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: January 31, 2025

Expiration: January 30, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Mark, a 42-year-old male with refractory moderate to severe atopic dermatitis (AD), has been struggling with intense itching, widespread lesions, and poor quality of life despite using topical corticosteroids and systemic corticosteroids for severe flares. His dermatologist is considering initiating a biologic therapy targeting interleukin (IL)-13.

Based on Mark’s clinical presentation and the mechanism of IL-13 in AD, what is the primary therapeutic benefit of choosing an IL-13–targeting biologic for his treatment?